ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Ann Thorac Surg 2008;85:844. doi:10.1016/j.athoracsur.2007.07.065
© 2008 The Society of Thoracic Surgeons
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Google Scholar
Right arrow Articles by Shander, A.
Right arrow Articles by Javidroozi, M.
PubMed
Right arrow Articles by Shander, A.
Right arrow Articles by Javidroozi, M.
Related Collections
Right arrow Extracorporeal circulation

Original Articles: Cardiovascular

Invited Commentary

Aryeh Shander, MD, FCCM, Mazyar Javidroozi, MD

Anesthesiology and Critical Care Medicine, Englewood Hospital and Medical Center, 350 Engle St, Englewood, NJ 07631

(Email: aryeh.shander@ehmc.com; mazyarjr@yahoo.com).

Level 1 evidence is seriously lagging behind the wide off-label use of recombinant activated factor VII (rFVIIa) in the control of massive or insurmountable bleeding. Dunkley and colleagues [1] have made a commendable effort in gathering and analyzing the data on nonhemophilia cardiac surgery cases with critical bleeding treated with rFVIIa from a large multicenter registry with financial support from Novo Nordisk. The study faces limitations, many of which are shared with other registries; lack of a control group is perhaps the biggest obstacle in interpreting the data, given the complicated . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 by The Society of Thoracic Surgeons.